The Filing Desk

Nurix Therapeutics

NRIX · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

NRIX · Last close · November 13, 2026
$15.48
Value Nurix Therapeutics yourself

Nurix Therapeutics' revenue rose 54.0% to $84 million in fiscal 2025. Its operating margin was −340.2%, up from −390.5% a year earlier. Free cash flow was −$263 million. The diluted share count rose 29.1%.

NURIX THERAPEUTICS, INC. Latest fiscal year ended November 30, 2025 10-K filed January 28, 2026 · 0001549595-26-000016 Updated
Revenue
$84M
54.0%
Operating margin
−340.2%
50.4 pts
Net income
−$264M
 
Free cash flow
−$263M
 
Return on equity
−49.6%
3.6 pts
Market cap
$1.8B
Nov 13 close
P/E
6.7x
On $2.30 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Nurix Therapeutics does

Nurix Therapeutics is a clinical-stage drug company that develops medicines based on targeted protein degradation. This approach is meant to mark harmful proteins for the cell's own disposal system rather than just block them. It targets cancer and inflammatory diseases and has not sold a product. It says its discovery engine uses machine learning.

Its own pipeline has three candidates in human trials: bexobrutideg, a degrader of a protein called BTK; zelebrudomide, which degrades BTK and two other proteins; and NX-1607, which blocks a protein called CBL-B that restrains immune cells. It also has earlier degraders in preclinical work.

Nurix also works with partners. Under collaborations with Gilead Sciences, Sanofi and Pfizer it has a partnered pipeline that includes a degrader of IRAK4, and for some candidates it keeps options to share in development, sales and profits in the United States. It has never earned revenue from product sales.

Its biggest risks, as it describes them

  • It has lost money since it began and may never be profitable.
  • It will need a lot more funding, which could dilute shareholders.
  • Its protein degradation approach is unproven.
  • Drug development is long and costly, and early trial results may not predict later ones.
  • Side effects found in trials could slow or stop development.
From Nurix Therapeutics's annual report on Form 10-K, filed January 28, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Nurix Therapeutics lost money in fiscal 2025: a net loss of $264 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments296309288610593
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio4.7x4.5x3.4x6.5x7.0x
Quick ratio4.7x4.5x3.4x6.5x7.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Nurix Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Nurix Therapeutics shares on the open market, and 3 insiders sold $4.2 million, $3.7 million of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 2, 2026Christine RingChief Legal OfficerSold plan5,787$25.76$149,048Form 4
Sep 1, 2026Gwenn HansenChief Scientific OfficerSold plan1,452$25.47$36,982Form 4
Aug 5, 2026Gwenn HansenChief Scientific OfficerSold plan4,356$25.00$108,900Form 4
Aug 4, 2026Houte Hans vanChief Financial OfficerSold plan4,761$24.36$115,995Form 4
Aug 4, 2026Gwenn HansenChief Scientific OfficerSold plan4,111$24.36$100,140Form 4
Aug 3, 2026Christine RingChief Legal OfficerSold plan16,589$23.05$382,376Form 4
Jul 30, 2026Gwenn HansenChief Scientific OfficerSold3,847$23.38$89,943Form 4
Jul 30, 2026Houte Hans vanChief Financial OfficerSold2,845$23.38$66,516Form 4
Jul 2, 2026Christine RingChief Legal OfficerSold plan11,008$23.56$259,348Form 4
Jun 25, 2026Christine RingChief Legal OfficerSold plan28,935$20.06$580,436Form 4
Jun 25, 2026Gwenn HansenChief Scientific OfficerSold plan5,394$20.00$107,880Form 4
Jun 2, 2026Christine RingChief Legal OfficerSold plan8,148$16.60$135,257Form 4
The latest 12 of 26 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−17.3%−362.5%−259.8%
Altman Z''−2.723.281.20
Accruals ratio−16.2%−4.1%−2.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Nurix Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Nurix TherapeuticsFY2554.0%−340.2%−313.7%———
Eton PharmaceuticalsFY25104.9%−1.1%12.8%−1.9%1.4x4Compare
Viridian TherapeuticsFY2523,359.9%−512.9%−390.8%———Compare
Kura OncologyFY2525.2%−449.9%−104.8%——3Compare
ZymeworksFY2538.9%−87.3%−32.6%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue31183039775484
Revenue growth—−42.7%67.0%29.8%99.3%−29.1%54.0%
Gross profit———————
Research and development4566116184189222317
Operating income−22−65−118−184−155−213−286
Net income−22−43−117−180−144−194−264
Diluted EPS (US$)−6.59−2.76−2.73−3.71−2.65−2.88−3.05
Diluted shares (millions)3164349546787
Cash flow
Cash from operations1−0−84−160−81−173−250
Capital expenditure256128914
Free cash flow−1−5−90−172−90−182−263
Dividends paid0000000
Share buybacks0000000
Acquisitions0000000
Stock-based compensation041628343438
Balance sheet at fiscal year end
Cash and short-term investments38281296309288610593
Debt incl. finance leases———————
Total assets44396477417356669688
Total liabilities54106134113155142149
Shareholders' equity−58290342304200527539
Margins and ratios
Gross margin———————
Operating margin−71.5%−364.7%−396.3%−476.0%−201.4%−390.5%−340.2%
Net margin−69.7%−242.7%−393.9%−466.9%−187.0%−354.9%−314.9%
Free cash flow margin−3.4%−26.0%−302.6%−445.4%−116.6%−333.4%−313.7%
Rule of 40 (growth + FCF margin)—−68.7%−235.7%−415.6%−17.3%−362.5%−259.8%
Return on capital———————
Return on equity—−37.2%−37.0%−55.8%−57.1%−53.2%−49.6%
Return on assets—−19.6%−26.9%−40.4%−37.3%−37.8%−39.0%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Nurix Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Nurix Therapeutics.